MET and non-small cell lung carcinoma: The MARIPOSA study evaluated amivantamab (EGFR-MET bispecific antibody) plus lazertinib (third-generation EGFR TKI) in previously untreated EGFR-mutated (exon 19 deletions or exon 21 L858R) advanced NSCLC, and showed favorable PFS in patients with BMs compared to osimertinib alone (HR 0.69; 95% 0.53–0.92) [33].